Hepatic hemangioma future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Nawal Muazam (talk | contribs) No edit summary |
Nawal Muazam (talk | contribs) No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}};{{AE}}{{NM}} | {{CMG}};{{AE}}{{NM}} | ||
==Overview== | ==Overview== | ||
== | ==Future or investigational therapies== | ||
* Transcatheter hepatic arterial embolization (TAE) | * Transcatheter hepatic arterial embolization (TAE) |
Revision as of 18:30, 27 October 2015
Hepatic hemangioma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Hepatic hemangioma future or investigational therapies On the Web |
American Roentgen Ray Society Images of Hepatic hemangioma future or investigational therapies |
FDA on Hepatic hemangioma future or investigational therapies |
CDC on Hepatic hemangioma future or investigational therapies |
Hepatic hemangioma future or investigational therapies in the news |
Blogs on Hepatic hemangioma future or investigational therapies |
Risk calculators and risk factors for Hepatic hemangioma future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
Future or investigational therapies
- Transcatheter hepatic arterial embolization (TAE)
- Radiofrequency ablation
- Orthotopic liver transplantation